Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.

Cancer research - 2 Apr 2026

Herzog Sarah K, Stevens Jessica H, Gu Guowei, Grimm Sandra L, Cardoza Kloma, Hawkins Autumn G M, Lin Hangqing, Ramos Daniela, Beyer Amanda R, Edwards David G, Dustin Derek, Yang Harry J, Liang Nicole, Khan Ashfia F, Bawa-Khalfe Tasneem, McGrail Daniel J, Lin Shiaw-Yih, Coarfa Cristian, Fuqua Suzanne A W

Abstract excerpt

ESR1 mutations are the leading cause of endocrine therapy resistance and progression in estrogen receptor (ER)-positive metastatic breast cancer. ESR1 mutations are detected in ∼50% of patients with metastatic breast cancer, and identification of effective targeted therapeutics is critically needed. In this study, we identified enrichment of dysregulated replication stress and DNA damage responses in multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Phthalazines

Share to Piperazines

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41499130
DOI: 10.1158/0008-5472.CAN-24-3891
PMCID: PMC12898867

Genes

ESR1
PARP1
CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.PMID 41499130Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast CancerSemantic proximity Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.Semantic proximity Read ↗

Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancerSemantic proximity Read ↗

Endocrine therapy resistance: new insights.Semantic proximity Read ↗

Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress toleranceSemantic proximity Read ↗

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Semantic proximity Read ↗

Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and RadiotherapySemantic proximity Read ↗

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ResistanceSemantic proximity Read ↗

XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cellsSemantic proximity Read ↗

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.